Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allogeneic Cardiosphere-Derived Cells · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Allogeneic Cardiosphere-Derived Cells (CAP-1002) | BIOLOGICAL | Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs) |
Allogeneic Cardiosphere-Derived Cells is an investigational cell therapy being studied for Duchenne Muscular Dystrophy, a genetic disorder that causes progressive muscle weakness and heart problems. It is being evaluated for its potential to halt cardiomyopathy progression in patients with this condition.
Allogeneic Cardiosphere-Derived Cells is being developed by Capricor Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CAPR. The company is conducting clinical trials to evaluate this investigational therapy for Duchenne Muscular Dystrophy.
Allogeneic Cardiosphere-Derived Cells is in Phase 2 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with Duchenne Muscular Dystrophy.
Allogeneic Cardiosphere-Derived Cells has been studied in two completed Phase 2 trials: NCT02485938, known as HOPE-Duchenne, which enrolled 25 patients with Duchenne Muscular Dystrophy and cardiomyopathy, and NCT06304064, known as HOPE-OLE, which enrolled 8 patients with Duchenne Muscular Dystrophy.
Allogeneic Cardiosphere-Derived Cells is the generic name for the investigational cell therapy developed by Capricor Therapeutics. It is also known by the brand name CAP-1002, which is the specific product candidate being studied in clinical trials for Duchenne Muscular Dystrophy.